The Impact of Neut During Potassium Chloride Replacement on Pain and Incidence of Phlebitis
| Status: | Enrolling by invitation |
|---|---|
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 2/7/2018 |
| Start Date: | February 2014 |
| End Date: | February 2019 |
The Impact of 4% Sodium Bicarbonate Additive During Potassium Chloride Replacement on Pain and Incidence of Phlebitis for Adult Patients in a Medical Surgical Unit: A Randomized Double Blinded Controlled Study
The purpose of this study is to examine the impact of 4% sodium bicarbonate additive during
peripheral intravenous potassium chloride replacement therapy for adult patients in a
Medical/Surgical unit. Using a randomized controlled double blinded experimental study
design, patients who are 21 years or older are alert, awake, and oriented at the time of
enrollment and have been ordered peripheral intravenous potassium chloride replacement will
be recruited from one Medical/Surgical during the first 24-48 hours of their admission.
peripheral intravenous potassium chloride replacement therapy for adult patients in a
Medical/Surgical unit. Using a randomized controlled double blinded experimental study
design, patients who are 21 years or older are alert, awake, and oriented at the time of
enrollment and have been ordered peripheral intravenous potassium chloride replacement will
be recruited from one Medical/Surgical during the first 24-48 hours of their admission.
The specific aim of the study is:
Aim 1: To compare patient outcomes (phlebitis, pain at peripheral IV insertion site,
frequency of changing IV access, and time for administration) between the experimental (4%
sodium bicarbonate additive during peripheral intravenous potassium chloride replacement
therapy) and control (standard of practice of no 4% sodium bicarbonate additive during
peripheral intravenous potassium chloride replacement therapy) groups.
Aim 2: To compare number and type of nursing interventions done during peripheral intravenous
potassium chloride replacement therapy between the experimental (4% sodium bicarbonate
additive during peripheral intravenous potassium chloride replacement therapy) and control
(standard of practice of no 4% sodium bicarbonate additive during peripheral intravenous
potassium chloride replacement therapy) groups.
Aim 3: To compare attrition rates and reasons between the experimental (4% sodium bicarbonate
additive during peripheral intravenous potassium chloride replacement therapy) and control
(standard of practice of no 4% sodium bicarbonate additive during peripheral intravenous
potassium chloride replacement therapy) groups.
Aim 1: To compare patient outcomes (phlebitis, pain at peripheral IV insertion site,
frequency of changing IV access, and time for administration) between the experimental (4%
sodium bicarbonate additive during peripheral intravenous potassium chloride replacement
therapy) and control (standard of practice of no 4% sodium bicarbonate additive during
peripheral intravenous potassium chloride replacement therapy) groups.
Aim 2: To compare number and type of nursing interventions done during peripheral intravenous
potassium chloride replacement therapy between the experimental (4% sodium bicarbonate
additive during peripheral intravenous potassium chloride replacement therapy) and control
(standard of practice of no 4% sodium bicarbonate additive during peripheral intravenous
potassium chloride replacement therapy) groups.
Aim 3: To compare attrition rates and reasons between the experimental (4% sodium bicarbonate
additive during peripheral intravenous potassium chloride replacement therapy) and control
(standard of practice of no 4% sodium bicarbonate additive during peripheral intravenous
potassium chloride replacement therapy) groups.
Inclusion Criteria:
- admitted to the medical/surgical unit within the last 24 to 48 hours
- awake, alert, and oriented times three
- 21 years old and greater
- receiving first peripheral intravenous potassium chloride replacement therapy as
ordered by physician or ARNP as part of care and regardless of research
- potassium level of 3.5 mmol/L or less.
Exclusion Criteria:
- patients who have been in the medical/surgical unit more than 48 hours.
- altered mental status defined as not being awake, alert, and oriented times three
- patients who already received intravenous potassium chloride replacement during the
current admission and with the current IV access
- patients receiving intravenous potassium replacement therapy through a central line
- patients that are not ordered potassium replacement by physician or ARNP as part of
their care while hospitalized.
We found this trial at
1
site
Click here to add this to my saved trials
